ADILHealthcare · BiotechnologyADIL Stock Forecast: Adial Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Adial Pharmaceuticals, Inc. hold a median 12-month price target of $7 — +92.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ADIL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Adial Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (11): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Adial Pharmaceuticals, Inc. — and when they’d sell — is the membership.
ADIL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ADIL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +92.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 June 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $6.00 |
| 15 June 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 30 Sept 2025 | Maxim Group | Upgrade | Buy | — |
| 14 Nov 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 12 July 2023 | Brookline Capital | Reiterates | Buy | — |
| 11 July 2023 | Brookline Capital | Reiterates | Buy | $6.00 |
| 17 Aug 2022 | Maxim Group | Downgrade | Hold | — |
| 13 Oct 2021 | Brookline Capital | Initiates | Buy | — |
| 29 June 2021 | Litchfield Hills | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ADIL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Adial Pharmaceuticals, Inc. (ADIL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 1.5×
- EV / EBITDA
- −0.3×
Cheaper than 73% of US stocks
Cheaper than 56% of US stocks
Cheaper than 64% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −265.9%
- Return on assets
- −108.7%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ADIL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADIL appears on the weeks it earns a place.
Frequently asked questions about ADIL stock
What is the ADIL stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Adial Pharmaceuticals, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ADIL stock a buy right now?
Of the 3 analysts covering Adial Pharmaceuticals, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adial Pharmaceuticals, Inc. 30 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ADIL?
As at 1 Aug 2026, Adial Pharmaceuticals, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
Will ADIL stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +92.3% from the last close, and Ticker Nerd's factor model ranks Adial Pharmaceuticals, Inc. 30 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ADIL stock forecast for 2030?
No analyst covering Adial Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADIL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.
How has ADIL stock performed over the past year?
Adial Pharmaceuticals, Inc. returned -68.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Adial Pharmaceuticals, Inc. do?
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment and prevention of addiction and related disorders.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment and prevention of addiction and related disorders. Its lead investigational product, AD04, is a genetically targeted serotonin-3 receptor antagonist designed specifically for Alcohol Use Disorder in patients with certain genotypes, identified through the company's proprietary companion diagnostic genetic test. This precision medicine approach aims to address unmet needs in addiction treatment by tailoring therapy to individual genetic profiles. Adial Pharmaceuticals Inc. is also advancing drug candidates for non-opioid pain reduction and other associated diseases and disorders. The company operates within the health technology sector, contributing to innovative solutions in pharmaceuticals for behavioral health challenges. Founded in 2010 and headquartered in Glen Allen, Virginia, Adial Pharmaceuticals Inc. emphasizes targeted therapies to improve outcomes in addiction management.
CEO Mr. Cary John Claiborne MBA · 5 employees · United States · https://www.adial.com